Multi-institutional analysis of robot-assisted partial nephrectomy for renal tumors \u3e4 cm versus ≤4 cm in 445 consecutive patients by Petros, Firas et al.




Multi-institutional analysis of robot-assisted partial
nephrectomy for renal tumors >4 cm versus ≤4 cm
in 445 consecutive patients
Firas Petros
Vattikuti Urology Institute, Henry Ford Health System
Shyam Sukumar
Vattikuti Urology Institute, Henry Ford Health System
Georges-Pascal Haber
Glickman Urological Institute, Cleveland Clinic Foundation
Lori Dulabon
New York University School of Medicine
Sam Bhayani
Washington University School of Medicine in St. Louis
See next page for additional authors
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Petros, Firas; Sukumar, Shyam; Haber, Georges-Pascal; Dulabon, Lori; Bhayani, Sam; Stifelman, Michael; Kaouk, Jihad; and Rogers,
Craig, ,"Multi-institutional analysis of robot-assisted partial nephrectomy for renal tumors >4 cm versus ≤4 cm in 445 consecutive
patients." Journal of Endourology.26,6. 642-646. (2012).
http://digitalcommons.wustl.edu/open_access_pubs/2795
Authors
Firas Petros, Shyam Sukumar, Georges-Pascal Haber, Lori Dulabon, Sam Bhayani, Michael Stifelman, Jihad
Kaouk, and Craig Rogers
This open access publication is available at Digital Commons@Becker: http://digitalcommons.wustl.edu/open_access_pubs/2795
Multi-Institutional Analysis of Robot-Assisted
Partial Nephrectomy for Renal Tumors > 4 cm
Versus £4 cm in 445 Consecutive Patients
Firas Petros, M.D.,1 Shyam Sukumar, M.D.,1 Georges-Pascal Haber, M.D.,2 Lori Dulabon, M.D.,3
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Abstract
Background and Purpose: Robot-assisted partial nephrectomy (RPN) has emerged as a viable approach to
minimally invasive surgery for small renal tumors. There are few reports of RPN for tumors > 4 cm. Our
objective was to evaluate outcomes of RPN for tumors > 4 cm compared with RPN for tumors £ 4 cm in a large
multi-institutional study.
Patients and Methods: We reviewed data for 445 consecutive patients who underwent RPN by experienced
surgeons at four academic institutions from 2006 to 2010. Patients were stratified into two groups according to
radiographic tumor size. Patient demographics, perioperative outcomes, and oncologic outcomes were recorded.
Results: A total of 83 of 445 (18.7%) patients had tumors > 4 cm with a median radiographic tumor size of 5.0 cm
(4.1–11 cm). Patients with tumors > 4 cm had a higher proportion of hilar tumors (9.8% vs 4.7%, P< 0.001), a
higher mean R.E.N.A.L. nephrometry score (8.0 vs 6.3, P < 0.01), longer warm ischemia time (WIT) (24 vs 17min,
P < 0.001), and an increased rate of collecting system repair (72.2% vs 51.6%, P = 0.006) compared with patients
with tumors £ 4 cm. Functional outcomes and complications were similar between groups. There were no
positive margins in patients with tumors > 4 cm and only one recurrence.
Conclusions: In the largest multi-institutional series of RPN for tumors > 4 cm, we demonstrate safety, feasibility,
and efficacy of RPN for tumors > 4 cm. Patients with tumors > 4 cm had a higher nephrometry score, longer
WIT, and slightly higher estimated blood loss compared with patients who had tumors £ 4 cm, but there was no
increased risk of adverse outcomes in the hands of experienced surgeons.
Introduction
Partial nephrectomy (PN) is the standard of care treat-ment option for small renal tumors that offers equivalent
oncologic efficacy to radical nephrectomy (RN)1,2 with
preservation of renal function and improved survival.1,3
Larger tumors pose additional technical challenges during
PN, particularly with a minimally invasive approach. The
technical feasibility of laparoscopic partial nephrectomy
(LPN) for tumors > 4 cm has been described,4,5 but consid-
erable surgeon experience is necessary, and complication
rates may be higher. Reports of robot-assisted partial ne-
phrectomy (RPN) for tumors > 4 cm are limited to a few
small single institution series.6,7 We report outcomes of RPN
for tumors > 4 cm compared with tumors £ 4 cm in a large
multicenter study.
Patients and Methods
Data acquisition and patient evaluation
After approval from our respective Institutional Review
Boards, we reviewed data for 445 consecutive patients who
underwent RPN by renal surgeons who were experienced in
minimally invasive techniques (SB, MS, JK, CR) at four insti-
tutions between June 2006 and April 2010. Maximum tumor
diameter was assessed radiographically by a board-certified
radiologist. Nephrometry score was assigned to renal tumors
using the R.E.N.A.L. (radius; exophytic/endophytic; near-
ness; anterior/posterior; location) tumor classification sys-
tem.8 For no patients was there preoperative suspicion of
localized or distant metastatic disease.
Patients were stratified into two groups based on radio-
graphic tumor size > 4 cm and £ 4 cm. Demographic and
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perioperative variables were assessed, including patient age,
body mass index (BMI), American Society of Anesthesiolo-
gists (ASA) score, operative time, warm ischemia time (WIT),
estimated blood loss (EBL), collecting system repair, compli-
cations (Clavien classification system9-Clavien II or greater
complications reported), length of hospital stay, histology,
tumor stage. and margin status. Estimated glomerular filtra-
tion rate (eGFR) was assessed preoperatively, at 1-month
follow-up, and at the most recent follow-up using the Mod-
ification of Diet in Renal Disease equation.10 A urine leak was
defined as biochemically proven urine drainage > 7 days
postoperatively or the need for an intervention (ie, ureteral
stent, nephrostomy, percutaneous drainage of urinoma, etc.).
All patients who were amenable for a minimally invasive
nephron-sparing procedure under warm ischemia, including
three patients with a solitary kidney, underwent RPN.
Surgical technique
The technique of RPN was similar among all surgeons and
has been described.11–14 The da Vinci robot system (Intuitive
Surgical Inc., Sunnyvale, CA) was used in all cases. Laparo-
scopic ultrasonograpy was used to evaluate tumor location
and extent. Hilar occlusion was performed in most cases, and
the tumor was resected using cold resection with robotic
scissors. A limited number of cases were performed without
hilar clamping for small tumors. For larger or endophytic
tumors, both the artery and the vein were clamped for im-
proved visualization during tumor resection.
Statistical analysis
We compared demographic, clinical, and tumor charac-
teristics of patients with tumors > 4 cm vs tumors £ 4 cm. The
assumption of normality was tested using the Shapiro-Wilk
normality test. All variables with the exception of maximum
tumor size were normally distributed. Variables were com-
pared between groups with tumors > 4 cm vs tumors £ 4 cm
using the Student t test and the Mann-Whitney U test. Sig-
nificance was set at 0.05 for each analysis. To control for
confounding and to examine the learning curve, a comparison
of categorical and continuous covariates was performed be-
tween the cases in the first (n = 222) and second half (n = 223) of
the study. All statistical analyses were performed using SAS
v9.2 for Windows (SAS Institute Inc, Cary, NC).
Results
A total of 83 (18.7%) patients had tumors > 4 cm, with a
median tumor size of 5.0 cm (4.1–11 cm). Nine of these pa-
tients had tumors > 7 cm (clinical stage T2); 362 (81.3%) pa-
tients had tumors £ 4 cm, with a median tumor size of 2.3 cm
(0.7–4 cm). Patient demographics and radiographic tumor
characteristics are summarized in Table 1. Patients with
tumors > 4 cm had a higher BMI (30.4 vs 28.2 kg/m2, P = 0.01)
and a higher proportion of tumors in a hilar location (9.8% vs
4.7%, P < 0.001). Patients with tumors > 4 cm had a higher
mean nephrometry score of 8.0 (n = 60 patients, range 4–11)
compared with a median nephrometry score of 6.3 for smaller
tumors (n = 228, range 4–10), P < 0.01.
Table 2 demonstrates operative outcomes by tumor size.
Patients with tumors > 4 cm had a longer mean WIT (24 vs
17min, P < 0.001), a higher operative time (194 vs 180min,
P = 0.017), EBL (200 vs 150mL, P = 0.001), length of hospital
stay (3 vs 2.5 days, P = 0.005), and higher rate of collecting
system repair (72.2% vs 51.6%, P = 0.006). Most cases in both
groups were performed with hilar clamping (93% vs 88%,
P = 0.25). There were no significant differences in functional
outcomes measured by eGFR between groups. The mean
percent decrease in eGFR at 1 month postoperatively was
greater for tumors > 4 cm (9% vs 4.5%), but this did not reach
statistical significance (P = 0.09). Preoperatively, 17.2% of pa-
tients with tumors > 4 cm and 13% of patients with tumors
Table 1. Patient Demographics for Robot-Assisted Partial Nephrectomy by Tumor Size
Variables Tumors > 4 cm (n = 83) Tumors £ 4 cm (n= 362) P value
Mean age, y (SD) 61 (12) 60 (11) 0.69
Sex, N (%)
Male 52 (62.7) 245 (67.7) 0.44
Body mass index, kg/m2a 30.4 (26.8–35.2) 28.2 (25.4–32.9) 0.01
ASA score 2 (2–3) 2 (2–3) 0.45
Mean preoperative creatinine, mg/dL, (SD) 1 (0.39) 0.98 (0.32) 0.68
Mean preoperative eGFR, (SD)b 81.7 (31.4) 82 (23) 0.94
Radiographic characteristics, N, (%)
Tumor size, cm (range) 5 (4.1–11) 2.3 (0.7–4) < 0.001
Upper pole 26 (32.1) 82 (23.8) 0.26
Midpolar 32 (39.5) 163 (47.2)
Lower pole 23 (28.4) 100 (29)
Endophytic 16 (25) 68 (25.7) 0.75
Mean nephrometry score (range)c 8.0 (4–11) 6.3 (4–10) < 0.01
Anterior, N (%) 23 (38.4) 99 (43)
Posterior 16 (26.6) 72 (32)
Neither 21 (35.0) 57 (25)
Hilar 5 (9.8) 9 (4.7)
aContinuous values are expressed as median (interquartile range) unless mentioned otherwise.
bCalculated using the Modification of Diet in Renal Disease equation.
cNephrometry score available in 60 patients with tumors > 4 cm and 228 patients with tumors £ 4 cm.
SD= standard deviation; ASA =American Sociaty of Anesthesiologists; eGFR= estimated glomerular filtration rate.
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£ 4 cmwere classified as having chronic kidney disease stage 3
or greater; the corresponding values in the postoperative pe-
riod (1 month) were 40.4 % and 27.6% for the two groups,
respectively.
Therewere no differences in complications between groups
(Table 3), and complications were either Clavien II or IIIa.
Postoperative complications of patients with tumors > 4 cm
included two urine leaks necessitating stent placement, one
bleed necessitating angioembolization, and a pulmonary
embolism in two patients. Two patients in the > 4 cm tumor
group underwent conversion to LPN because of equipment
malfunction early in our experience, but there was no differ-
ence in conversions between groups.
Table 3 lists pathologic characteristics of the tumors. There
was no difference in the rate of malignancy between groups.
The mean pathologic tumor size was 4.8 cm vs 2.2 cm
(P < 0.001), similar to the comparison of radiographic tumor
size. There were no positive surgical margins in patients with
tumors > 4 cm. There were seven focally microscopic positive
margins on final pathologic evaluation in patients with
tumors £ 4 cm, resulting in a positive margin rate of 1.9%.
Two of these tumors were benign (lipid-poor angiomyolipo-
mas not clearly evident on preoperative radiographic imag-
ing). There was only one local recurrence in a patient with a
tumor > 4 cm and high-grade pT3a renal-cell carcinoma (RCC)
with negative margins. No other patient had evidence of re-
currence or metastatic disease at a maximum of 45 months
follow-up (mean 10 months).
When comparing outcomes in the first and second half of
our RPN experience, there was no difference in the percentage
of tumors > 4 cm (15.7% vs 17.0%, P = 0.46). There were no
statistically significant differences in operative parameters,
such as WIT or positive margin rate, except for a slightly
shorter operative time in the later cohort (189 vs 175min,
P < 0.05).
Discussion
As the role of nephron-sparing surgery (NSS) expands
minimally invasive techniques of PN have been applied to
Table 2. Operative Outcomes for Robot-Assisted Partial Nephrectomy by Tumor Size
Variables Tumors > 4 cm (n = 83) Tumors £ 4 cm (n = 362) P value
Operative time, mina 194 (153–240) 180 (147–220) 0.017
Mean warm ischemia time, min (SD, range) 24 (10, 0–45) 17 (9, 0–60) < 0.001
Estimated blood loss, mL 200 (100–400) 150 (100–250) 0.001
Hilar clamping, N (%) 77 (93) 319 (88) 0.25
Collecting system repair, N (%) 39 (72.2) 114 (51.6) 0.006
Blood transfusions, N (%) 10 (12) 10 (3) 0.001
Conversions, N (%)
Robot-assisted RN 0 (0) 2 (0.55) 1.00
Conventional laparoscopic PN 2 (2.4) 2 (0.55) 0.16
Open RN 0 (0) 1 (0.28) 1.00
Length of stay, d 3 (2–4) 2.5 (2–3) 0.005
Mean percent decrease eGFR at 1 month (SD) 9% (11) 4.5% (15) 0.09
Mean percent decrease eGFR at last follow-up (SD) 8.6 % (16.5) 3.9 % (17.4) 0.11
aContinuous values are expressed as median (interquartile range) unless mentioned otherwise.
SD= standard deviation; RN= radical nephrectomy; PN=partial nephrectomy; eGFR= estimated glomerular filtration rate
Table 3. Postoperative Outcomes of Robot-Assisted Partial Nephrectomy by Tumor Size
Variables
Tumors
> 4 cm (n = 83)
Tumors
£ 4 cm (n= 362)
P
value
Tumor histology, N (%)
Clear-cell RCC 40 (48.2) 180 (50.3) 0.41
Other RCC 18 (21.7) 81 (22.6)
Other malignant 2 (2.4) 11 (3.1)
Benign 23 (27.7) 86 (24)
Tumor stage





Positive margins, N (%) 0 (0) 5 (1.4) 0.35
Complications, N (%) 5 (8.4) 14 (3.9) 0.37
Urine leak necessitating intervention 2 (2.4) 3 (0.83) 0.23
Postoperative bleed/pseudoaneurysm necessitating intervention 1 (1.2) 5 (1.38) 1.00
Pulmonary embolism/DVT 2 (2.4) 6 (1.66) 0.65
RCC= renal-cell carcinoma; DVT=deep vein thrombosis.
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more complex renal tumors. Recent guidelines15,16 for RCC
have recommended the use of NSS for T1 renal tumors
whenever feasible, regardless of tumor diameter. Open PN
has been shown to be safe and feasible in selected patients
with 4 to 7 cm renal tumors with outcomes comparable to
those of RN2,17 and with evidence suggesting reduced car-
diovascular events and improved survival over RN,18 similar
to what has been demonstrated with T1a tumors. Large
tumors may present additional technical challenges even for
surgeons experienced in minimally invasive techniques. RPN
has been demonstrated to be safe and feasible for challenging
renal tumors, such as large and hilar renal masses.6,7,19
The aim of our study was to demonstrate the feasibility of
RPN for tumors > 4 cm and to emphasize that robotic assis-
tance may offer advantages even for surgeons who are ex-
perienced in minimally invasive techniques.
Ourmulticenter study includes 83 patients who underwent
RPN for tumors > 4 cm, making it the largest study of mini-
mally invasive PN for tumors > 4 cm by any approach. Pa-
tients with tumors > 4 cmhad a longerWIT (24 vs 17min). The
WIT in our series, however, was well below the targeted goal
of £ 30 minutes in both groups. The longer mean WIT ob-
served for large tumors is consistent with previous smaller
single institution reports of RPN for tumors > 4 cm.4,6 The
increased complexity of the group with tumors > 4 cm as
evidenced by the higher nephrometry score and higher rates
of collecting system repair likely influenced the differences
seen in WIT. Although tumors > 4 cm had higher opera-
tive times and EBL in comparison with tumors £ 4 cm that
achieved statistical significance, the clinical significance is
debatable.
The feasibility of PN for tumors > 4 cm has been described
for LPN4,5 by experienced laparoscopic surgeons. A series by
Simmons and associates4 included 58 patients who under-
went LPN for tumors > 4 cm with a mean WIT of 38 minutes.
Another series that included 34 patients who underwent LPN
for tumors > 4 cm did not include data on WIT, but patients
with tumors > 4 cm had a higher rate of complications than
patients with tumors £ 4 cm (37% vs 21.8%).5 Robotic assis-
tance may help surgeons achieve shorter WIT. Results of a
large comparative study of RPN vs LPN found that WIT was
shorter in the RPN group (19.7 vs 28.4min) even for surgeons
who were experienced in minimally invasive techniques, and
this trend continuedwith more complex tumors.13We did not
routinely use early unclamping techniques in our study,
which has been shown to reduce WIT during LPN,20 but we
would expect the WIT for RPN to further decrease with ap-
plication of this technique.
Two small single-institution studies have evaluated RPN
for tumors > 4 cm. Patel and colleagues6 reported on RPN for
15 patients with tumors > 4 cm and compared outcomes with
56 patients with tumors £ 4 cm. Patients with tumors > 4 cm
had a longer median WIT (25 vs 20min, P = 0.011). Gupta and
coworkers7 reported on 17 patients with tumors > 4 cm (me-
dian tumor size, 5 cm), with a median EBL of 500mL, median
operative time of 390minutes, andmedianWIT of 36minutes.
They attributed these outcomes to a higher median ne-
phrometry score of 9 (6–11), a multifocality rate of 42%, and
the fact that 89.5% of tumors were > 50% endophytic. In our
study of 83 patients with tumors > 4 cm,we achieved aWIT of
24 minutes despite equivalent median tumor size (5 cm) and
tumors that were also complex (median nephrometry score, 8;
collecting system repair rate, 72%) and with no positive sur-
gical margins.
Surgeon experience and patient selection likely contribute
to successful RPN, particularly for tumors > 4 cm. Learning
curve effects did not appear to have a major impact on our
results, as surrogate end points such as the proportion of
tumors > 4 cm attempted, positive surgical margins, andWIT
did not change significantly between the first and second half
of the study. The lack of a learning curve detection in our
studymay be in part because all surgeonswere experienced in
laparoscopic and robotic techniques, and all surgeons per-
formed complicated cases early in the series.
Limitations of our study include the retrospective nature
and selection biases of a nonrandomized surgical cohort.
R.E.N.A.L nephrometry scores and estimated creatinine
clearance were available for most, but not all patients. There is
emerging interest in controlling for case complexity with ne-
phrometry scoring systems, but these systems await valida-
tion and may be of limited utility in a cohort selected for
homogeneity such as ours, in which all patients with tumors
> 4 cm had tumors amenable to RPN.We used ameasurement
of tumor size based on the maximum tumor dimension on
preoperative imaging. Although this size measurement has
inherent limitations and does not include tumor volume, this
was the variable collected in our prospective database. Long-
term follow-upwas not available for all patients in our dataset
becausemany patients were referred to our respective tertiary
medical centers and received long-term follow-up by their
local urologists. Further studies to evaluate the long-term
outcomes of RPN for tumors > 4 cm are warranted.
Conclusions
In the largest multi-institutional series of RPN for tumors
> 4 cm, we demonstrate safety, feasibility, and efficacy of RPN
for tumors > 4 cm. Tumors > 4 cm had a higher nephrometry
score, longer WIT, and a slightly higher EBL compared with
tumors £ 4 cm, but there was no increased risk of adverse
outcomes in the hands of experienced surgeons.
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